SIBN Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -9.38% compared to SI-BONE, Inc.'s net margin of 12.65%. SI-BONE, Inc.'s return on equity of -12.92% beat Electromed, Inc.'s return on equity of 18.89%.

SI-BONE, Inc. has a consensus price target of $25.89, signalling upside risk potential of 27.16%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that SI-BONE, Inc. has higher upside potential than Electromed, Inc., analysts believe SI-BONE, Inc. is more attractive than Electromed, Inc..

SI-BONE, Inc. has a beta of 0.756, which suggesting that the stock is 24.352% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

SI-BONE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SI-BONE, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

SI-BONE, Inc. quarterly revenues are $48.7M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. SI-BONE, Inc.'s net income of -$4.6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, SI-BONE, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SI-BONE, Inc. is 4.48x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -9.38% compared to SI-BONE, Inc.'s net margin of -12.6%. SI-BONE, Inc.'s return on equity of -12.92% beat IRIDEX Corp.'s return on equity of -155.93%.

SI-BONE, Inc. has a consensus price target of $25.89, signalling upside risk potential of 27.16%. On the other hand IRIDEX Corp. has an analysts' consensus of -- which suggests that it could grow by 75.44%. Given that IRIDEX Corp. has higher upside potential than SI-BONE, Inc., analysts believe IRIDEX Corp. is more attractive than SI-BONE, Inc..

SI-BONE, Inc. has a beta of 0.756, which suggesting that the stock is 24.352% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.842%.

SI-BONE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SI-BONE, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

SI-BONE, Inc. quarterly revenues are $48.7M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. SI-BONE, Inc.'s net income of -$4.6M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, SI-BONE, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SI-BONE, Inc. is 4.48x versus 0.38x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -9.38% compared to SI-BONE, Inc.'s net margin of -36.3%. SI-BONE, Inc.'s return on equity of -12.92% beat Myomo, Inc.'s return on equity of -68.35%.

SI-BONE, Inc. has a consensus price target of $25.89, signalling upside risk potential of 27.16%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than SI-BONE, Inc., analysts believe Myomo, Inc. is more attractive than SI-BONE, Inc..

SI-BONE, Inc. has a beta of 0.756, which suggesting that the stock is 24.352% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

SI-BONE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SI-BONE, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

SI-BONE, Inc. quarterly revenues are $48.7M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. SI-BONE, Inc.'s net income of -$4.6M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, SI-BONE, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SI-BONE, Inc. is 4.48x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of -9.38% compared to SI-BONE, Inc.'s net margin of -86.59%. SI-BONE, Inc.'s return on equity of -12.92% beat Stereotaxis, Inc.'s return on equity of -218.3%.

SI-BONE, Inc. has a consensus price target of $25.89, signalling upside risk potential of 27.16%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 72.84%. Given that Stereotaxis, Inc. has higher upside potential than SI-BONE, Inc., analysts believe Stereotaxis, Inc. is more attractive than SI-BONE, Inc..

SI-BONE, Inc. has a beta of 0.756, which suggesting that the stock is 24.352% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

SI-BONE, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SI-BONE, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

SI-BONE, Inc. quarterly revenues are $48.7M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. SI-BONE, Inc.'s net income of -$4.6M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, SI-BONE, Inc.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SI-BONE, Inc. is 4.48x versus 7.16x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.